Additionally, our study suggests LKB1 loss as a genotypic marker for sensitivity to KRASG12C-selective inhibitors + MCL-1 inhibitors in LKB1-deficient KRAS-mutant lung cancer cells. This evidence concerns the gene KRAS and lung carcinoma.